166 related articles for article (PubMed ID: 36273457)
21. Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas.
López-Álvarez M; González-Aguilera C; Moura DS; Sánchez-Bustos P; Mondaza-Hernández JL; Martín-Ruiz M; Renshaw M; Ramos R; Castilla C; Blanco-Alcaina E; Hindi N; Martín-Broto J
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614121
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
Dickson MA; Mahoney MR; Tap WD; D'Angelo SP; Keohan ML; Van Tine BA; Agulnik M; Horvath LE; Nair JS; Schwartz GK
Ann Oncol; 2016 Oct; 27(10):1855-60. PubMed ID: 27502708
[TBL] [Abstract][Full Text] [Related]
23. Trabectedin for Advanced Soft Tissue Sarcoma: Ten Year Real-Life Perspective.
Shamai S; Merimsky O
Isr Med Assoc J; 2018 Oct; 20(10):599-603. PubMed ID: 30324774
[TBL] [Abstract][Full Text] [Related]
24. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
[TBL] [Abstract][Full Text] [Related]
25. Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line.
Nakano K; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Tomomatsu J; Ono M; Taira S; Nishizawa M; Wang X; Ohmoto A; Sato Y; Fukuda N; Urasaki T; Takahashi S
Mol Clin Oncol; 2021 Jan; 14(1):13. PubMed ID: 33282288
[TBL] [Abstract][Full Text] [Related]
26. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study.
Blay JY; Schöffski P; Bauer S; Krarup-Hansen A; Benson C; D'Adamo DR; Jia Y; Maki RG
Br J Cancer; 2019 May; 120(11):1026-1032. PubMed ID: 31065111
[TBL] [Abstract][Full Text] [Related]
27. Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study.
Kawai A; Narahara H; Takahashi S; Nakamura T; Kobayashi H; Megumi Y; Matsuoka T; Kobayashi E
BMC Cancer; 2022 May; 22(1):528. PubMed ID: 35546669
[TBL] [Abstract][Full Text] [Related]
28. Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.
Hoiczyk M; Grabellus F; Podleska L; Ahrens M; Schwindenhammer B; Taeger G; Pöttgen C; Schuler M; Bauer S
Int J Oncol; 2013 Jul; 43(1):23-8. PubMed ID: 23652821
[TBL] [Abstract][Full Text] [Related]
29. Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma.
Martorana F; Vigneri P; Manzella L; Tirrò E; Soto Parra HJ
Future Oncol; 2020 Jan; 16(1s):9-13. PubMed ID: 31916463
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Eribulin in Soft Tissue Sarcomas.
Phillips E; Jones RL; Huang P; Digklia A
Front Pharmacol; 2022; 13():869754. PubMed ID: 35444542
[TBL] [Abstract][Full Text] [Related]
31. Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma.
Liu W; Tong H; Zhang C; Zhuang R; Guo H; Lv C; Yang H; Lin Q; Guo X; Wang Z; Wang Y; Shen F; Wang S; Dai C; Wang G; Liu J; Lu W; Zhang Y; Zhou Y
BMC Cancer; 2020 Oct; 20(1):1035. PubMed ID: 33115433
[TBL] [Abstract][Full Text] [Related]
32. Eribulin Shows Promise in Advanced Sarcoma.
Cancer Discov; 2015 Jul; 5(7):OF4. PubMed ID: 26045011
[No Abstract] [Full Text] [Related]
33. Lipoleiomyosarcoma (well-differentiated liposarcoma with leiomyosarcomatous differentiation): a clinicopathologic study of nine cases including one with dedifferentiation.
Folpe AL; Weiss SW
Am J Surg Pathol; 2002 Jun; 26(6):742-9. PubMed ID: 12023578
[TBL] [Abstract][Full Text] [Related]
34. The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study.
Nakamura T; Tsukushi S; Asanuma K; Katagiri H; Ikuta K; Nagano A; Kozawa E; Yamada S; Shido Y; Yamada K; Kawanami K; Ishimura D; Sudo A; Nishida Y
Clin Exp Metastasis; 2019 Aug; 36(4):343-350. PubMed ID: 31209624
[TBL] [Abstract][Full Text] [Related]
35. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD; von Mehren M; Jones RL; Hensley ML; Schuetze SM; Staddon A; Milhem M; Elias A; Ganjoo K; Tawbi H; Van Tine BA; Spira A; Dean A; Khokhar NZ; Park YC; Knoblauch RE; Parekh TV; Maki RG; Patel SR
J Clin Oncol; 2016 Mar; 34(8):786-93. PubMed ID: 26371143
[TBL] [Abstract][Full Text] [Related]
37. A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin.
Inagaki C; Shimoi T; Okuma H; Kitano A; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Yoshida A; Fujiwara Y; Tamura K
Anticancer Drugs; 2018 Jan; 29(1):97-101. PubMed ID: 29176397
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy and safety of combination therapy with chemotherapy, programmed death-1 inhibitor and anlotinib in the treatment of advanced dedifferentiated liposarcoma].
Guo X; Zhuang RY; Zhou YH; You CL; Zhang Y; Feng F; Shen ZM; Wang WS; Liu Y; Zhang HX; Tong WQ; Lu RK; Luo R
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2428-2434. PubMed ID: 36000371
[No Abstract] [Full Text] [Related]
39. Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma.
De Vita A; Miserocchi G; Recine F; Mercatali L; Pieri F; Medri L; Bongiovanni A; Cavaliere D; Liverani C; Spadazzi C; Amadori D; Ibrahim T
Molecules; 2016 Dec; 21(12):. PubMed ID: 27918490
[TBL] [Abstract][Full Text] [Related]
40. New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC - Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas.
Kantidakis G; Litière S; Neven A; Vinches M; Judson I; Blay JY; Wardelmann E; Stacchiotti S; D'Ambrosio L; Marréaud S; van der Graaf WTA; Kasper B; Fiocco M; Gelderblom H
Eur J Cancer; 2022 Oct; 174():261-276. PubMed ID: 36116829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
